Current and potential imaging applications of ferumoxytol for magnetic resonance imaging

Gerda B. Toth 1,21, Csanad G. Varallyay 2,21, Andrea Horvath 1,21, Mustafa R. Bashir 3,4, Peter L. Choyke 5, Heike E. Daldrup-Link 6, Edit Dosa 7, John Paul Finn 8, Seymur Gahramanov 9, Mukesh Harisinghani 10, Iain Macdougall 11, Alexander Neuwelt 12, Shreyas S. Vasawarna 13, Prakash Ambady 14, Ramon Barajas 15, Justin S. Cetas 14, Jeremy Ciporen 14, Thomas J. DeLoughery 15, Nancy D. Doolittle 1, Rongwei Yu 16,17, John Grinstead 18, Alexander R. Guimaraes 2, Bronwyn E. Hamilton 2, Xin Li 19, Heather L. McConnell 1, Leslie L. Muldoon 1, Gary Nesbit 3, Joao P. Netto 1,2, David Petterson 2, William D. Rooney 19, Daniel Schwartz 1,19, Laszlo Szidonya 1 and Edward A. Neuwelt 1,14,20

1Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA; 2Department of Radiology, Oregon Health & Science University, Portland, Oregon, USA; 3Department of Radiology, Duke University Medical Center, 3808, Durham, North Carolina, USA; 4Department of Radiology, University of Colorado Denver, Aurora, Colorado, USA; 5Department of Hematology and Oncology, Oregon Health & Science University, Portland, Oregon, USA; 6Department of Radiology, Stanford University, Stanford, California, USA; 7Heart and Vascular Center, Semmelweis University, Budapest, Hungary; 8Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, California, USA; 9Department of Neurosurgery, University of New Mexico Health Sciences Center, Albuquerque, New Mexico, USA; 10Department of Radiology, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA; 11Department of Renal Medicine, King’s College Hospital, London, UK; 12Division of Medical Oncology, University of Colorado Denver, Aurora, Colorado, USA; 13Department of Radiology, Stanford University, Stanford, California, USA; 14Department of Neurosurgery, Oregon Health & Science University, Portland, Oregon, USA; 15Department of Hematology and Medical Oncology, Oregon Health & Science University, Portland, Oregon, USA; 16School of Public Health, Oregon Health & Science University, Portland, Oregon, USA; 17Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland, Oregon, USA; 18Siemens AG, Healthcare Center, Portland, Oregon, USA; 19Advanced Imaging Research Center, Oregon Health & Science University, Portland, Oregon, USA; and 20Portland Veterans Affairs Medical Center, Portland, Oregon, USA

Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material.

Kidney International (2017) 1, –; http://dx.doi.org/10.1016/j.kint.2016.12.037

KEYWORDS: chronic kidney disease; magnetic resonance imaging; nephrotoxicity
Published by Elsevier, Inc., on behalf of the International Society of Nephrology.

PURPOSE OF THIS REVIEW
Since the US Food and Drug Administration (FDA) approved ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA, USA) to treat iron deficiency anemia in adults with chronic kidney disease (CKD) in 2009, the off-label use of this iron oxide nanoparticle compound by clinicians and researchers as a magnetic resonance imaging (MRI) contrast agent has rapidly grown. Ferumoxytol-enhanced imaging is feasible in patients with impaired renal function, a patient population in whom both gadolinium and iodinated contrast agents are contraindicated. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. Furthermore, because iron is a naturally occurring element in the body, the administered iron enters the body’s natural iron metabolic pathways. Thus, the use of ferumoxytol is not currently associated with concerns regarding long-term deposition, as is the case with brain deposition of gadolinium-containing agents.1–4
There are 2 aims of this review: first, to draw attention to a viable option of contrast-enhanced cross-sectional imaging in patients with renal failure; therefore, *Kidney International* was chosen for publication, and second, to highlight the growing body of literature that explores a variety of clinical indications that suggest ferumoxytol has utility not only as an alternative to gadolinium-based contrast agents (GBCAs) but also as a specialized MRI contrast agent with unique properties.

The number of clinical trials that use ferumoxytol as a contrast agent is increasing. The coauthors are experienced in the imaging of the central nervous system (CNS), body, and cardiovascular system with ferumoxytol. Based on the recommendations of the coauthors, we collected relevant articles in the literature focusing on ferumoxytol over other ultrasmall superparamagnetic iron oxides (USPIOs) and highlighted the clinical applications rather than the preclinical investigations.

This article describes ferumoxytol administration, dosing, and timing for imaging applications, followed by organ-specific utilizations. We created an atlas (Supplementary Material 1) that more fully describes the application of ferumoxytol throughout the body and a table of relevant clinical publications (Supplementary Material 2) that use ferumoxytol, both of which can be found in the online supplement.

**FERUMOXYTOL AS AN IRON REPLACEMENT**

I.v. iron supplementation is important in patients with CKD owing to poor gastric absorption of oral iron. Insufficient absorption is related to the upregulation of hepcidin that occurs in CKD, which is exacerbated by excessive iron losses.

Although widely used, iron dextran, iron sucrose, and iron sodium gluconate have significant clinical limitations. Over the last decade, 3 new i.v. iron preparations have been developed that display tighter iron binding, allowing greater doses of iron to be given in a single administration. Along with ferric carboxymaltose and iron isomaltoside 1000, ferumoxytol has entered the therapeutic arena as an effective iron supplement. Ferumoxytol has favorable physicochemical characteristics, potentially reducing amounts of circulating free iron. Multiple studies have reported effective and safe treatments of iron deficiency with ferumoxytol.

**FERUMOXYTOL IN MRI**

Initially, ferumoxytol was developed as an MRI contrast agent because of its effectiveness in shortening T1 and T2 relaxation times. Licensing the drug as a therapeutic iron supplement was a strategic decision, but this compound still holds great potential as an MRI contrast agent. Satisfactory contrast-enhanced imaging can be performed with doses as low as 1 mg/kg and as high as a 510 mg total dose. See Figure 1 for the potential imaging phases following i.v. administration.

Arterial-venous dynamic phase: T2*-based dynamic susceptibility contrast perfusion imaging of the brain requires only 1 mg/kg ferumoxytol and provides parametric maps of the brain similar to those achieved with a standard dose of gadolinium. The lack of early contrast extravasation with ferumoxytol is beneficial in cardiovascular and peripheral vascular examinations, wherein T1-weighted images acquired using a 4-mg/kg bolus injection clearly show intravascular enhancement as hyperintense structures. Although there is no evidence that these small bolus injections carry a higher risk of adverse events, rapid injection of ferumoxytol is not currently recommended by the FDA.

Blood pool phase: One of the major advantages of nanoparticle imaging is the relatively long circulating time, with ferumoxytol displaying a plasma half-life of 14 to 21 hours. Even in highly permeable tumors, high-resolution imaging of the intravascular space can be achieved without visible background tissue enhancement. Steady-state blood volume mapping of the brain is a T2*-based technique that requires 3 to 7 mg/kg ferumoxytol whereas T1-based steady-state angiography of the peripheral vessels is performed using 3 to 4 mg/kg.

Delayed phase: In brain lesions, slow leakage of ferumoxytol through the disrupted blood-brain barrier results in MRI signal changes peaking around 24 hours after ferumoxytol administration. T1-weighted MRI shows signal increase similar to those observed with gadolinium. A signal decrease on T2/T2*-weighted images may represent high local iron concentration and/or intracellular uptake, which has many useful applications outside of the CNS. Indeed, the intracellular uptake of ferumoxytol in abdominal organs, lymph nodes, and vascular walls can be used to effectively delineate pathology in these areas.

It is important to note that if a subsequent MRI is needed within 72 hours, ferumoxytol contrast enhancement may still be present in brain pathologies several days following administration. In addition, decreased signal intensities in the liver, spleen, and bone marrow scans may persist for several months before returning to baseline.

**FERUMOXYTOL METABOLISM AND CLEARANCE**

Following extravasation, ferumoxytol nanoparticles are taken up by cells of the mononuclear phagocyte system (MPS, previously known as the reticuloendothelial system), primarily in the liver, spleen, and bone marrow. In the brain, macrophages or astrocytes contribute to ferumoxytol clearance. Within these phagocytic cells, the nanoparticles are stored in secondary lysosomes. The carboxymethyl dextran coating is cleaved by dextranase and the cleaved coating is completely excreted by the kidneys and/or eliminated through feces. The iron core is incorporated into the body’s iron stores and used for cell metabolism and hemoglobin synthesis. Unless the patient has known hemosiderosis or hemochromatosis, the administered iron during MRI examination (maximum, 510 mg) is safe, and no overloading occurs.

Table 1 summarizes the physical, pharmacokinetic, and imaging properties of ferumoxytol compared with those of gadolinium.

**FERUMOXYTOL SAFETY**

On March 30, 2015, the FDA revised the prescribing information of Feraheme to include the addition of a boxed
warning, which highlighted potential fatal and serious hypersensitivity reactions, including anaphylaxis. The warning emphasized the importance of trained personnel, appropriate medications being readily available, and monitoring patients for at least 30 minutes following administration to properly screen for hypersensitivity reactions. In the 3 premarketing clinical trials of Feraheme, including 1164 patients, the aggregate rate of anaphylaxis was 0.2%. The postmarketing trials had even better results; the largest trial with 8666 patients showed a serious adverse event rate of 0.2% and an anaphylaxis rate of 0.02%. Recently, several studies described the diagnostic use of ferumoxytol in MRI, with no serious adverse events being reported. The frequency of ferumoxytol-related adverse events (10%–14.6%) and serious adverse events (0%–1%) were comparable in all investigations, with rates similar to those seen with ionic iodinated contrast agents, and were 10 times higher than gadolinium-related events. The initial administration rate of a 510 mg bolus over 17 seconds was lowered to a slow infusion of 510-mg-diluted ferumoxytol over 15 minutes, as suggested by the FDA recommendation. By reducing the rate of administration, the frequency of these events may also be reduced.

Ferumoxytol has also shown an excellent safety profile in pediatric patients. Typical doses of 1 to 5 mg/kg for imaging purposes are much lower than the therapeutic dose and do not have a significant effect on hemoglobin values.

**CNS MRI with Ferumoxytol**

Table 2 and Figure 3 indicate the most commonly used imaging sequences in the CNS.

**Intracranial Neoplasms**

The use of ferumoxytol in MRI of primary brain tumors has been extensively studied. While lesion visualization with ferumoxytol is generally similar to that with GBCAs, differences in enhancement patterns may help in the differential diagnosis. Perfusion MRI and steady-state blood volume mapping may improve tumor grading by identifying the most malignant area for surgical targeting and therapy monitoring.

**Lesion Visualization.** Contrast-enhanced MRI is routinely performed for the diagnosis of brain tumors, where the enhancement is the marker of the blood-brain barrier breakdown. Because extravasation of large molecules is slow, parenchymal enhancement is best seen in the delayed phase, 24 hours following ferumoxytol injection. Contrast enhancement found on various clinically used T1-weighted MRI sequences improves border delineation and enables assessment of lesion internal morphology (Figure 4). In primary malignant brain tumors, contrast enhancement with ferumoxytol is comparable with GBCA enhancement. No significant differences were found in the number of enhancing masses when gadolinium MRI and ferumoxytol MRI were compared in various primary brain tumors and metastatic lesions. Differences in GBCA and ferumoxytol enhancement size and intensity may be present, and they may reflect the differences in pathology, contrast agent dose, or timing of imaging. No difference was found in the enhancement size with the 2 contrast agents in metastatic lesions or untreated glioma patients. Decreased signal on T2-weighted images in the delayed phase may indicate high local ferumoxytol concentration or retention in tumor-associated macrophages. Delayed T1 and T2 enhancement together may help differentiate extracellular iron (e.g., tumor
Figure 2 | Ferumoxytol traffics from systemic circulation to reactive lesions: immunocompetent rat xenograft model demonstrating extravascular accumulation of ferumoxytol that correlates to the presence of activated macrophages. (a) Enhancement of the magnetic resonance imaging (MRI) signal occurred in xenografted but not saline-injected hemispheres. Blue arrows indicate marked hypointense signal on T1 MRI that correlates with histologic findings of intense immunostaining of ferumoxytol in macrophages using dextran-1 (Dx1). Yellow arrows indicate typical hyperintense enhancement on T1 MRI that correlates with diffuse milder staining for ferumoxytol in the brain parenchyma and activated astrocytes using Dx1. White arrowhead indicates no signal change after saline injection in the contralateral control hemisphere. (b) Immunostaining demonstrates that ferumoxytol traffics from the systemic circulation to reactive central nervous system lesions. Immunostaining performed 48 hours after H460 non–small-cell lung carcinoma inoculation into caudate nucleus and 24 hours after i.v. ferumoxytol administration. A representative inflammatory lesion was immunostained with Dx1 to observe the ferumoxytol coating (red), cluster of differentiation (CD)163 for macrophages (brown), and glial fibrillary acidic protein (GFAP) for astrocytes (brown). All cell nuclei were counterstained with hematoxylin. T denotes live tumor cells. Arrowheads indicate reactive cells located outside of the main lesion. (Continued)
Typical times to peak enhancement (in brain lesions) 24 h
Permeability to intact BBB Minimal Minimal
Relative size of the particle Approximately 30 nm 0.35 nm
Excretion Stored with the body
Imaging dose 1
Distribution Dynamic phase, blood pool phase, delayed
Signal change on T2*-weighted sequence Decreased signal Decreased signal if given
Signal change on T2-weighted sequence Usually no change
Relaxometric properties at 1.5 T/mM per s, 37 °C

<table>
<thead>
<tr>
<th>Feature</th>
<th>Ferumoxytol</th>
<th>Gd-DTPA (Magnevist)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basic element</td>
<td>Iron oxide coated with semisynthetic carbohydrate</td>
<td>Gadolinium(III) chelated with diethylenetriamine penta-acetic acid</td>
</tr>
<tr>
<td>Relaxometric properties at 1.5 T/mM per s, 37 °C in water</td>
<td>$r_1 = 15, r_2 = 89^{107}$</td>
<td>$r_1 = 3.3, r_2 = 3.9^{108}$</td>
</tr>
<tr>
<td>Elimination plasma half-life</td>
<td>14 h $^{106}$</td>
<td>1.6 h</td>
</tr>
<tr>
<td>Relative size of the particle</td>
<td>Approximately 30 nm $^{109}$</td>
<td>0.357 nm</td>
</tr>
<tr>
<td>Permeability to intact BBB</td>
<td>Minimal</td>
<td>Minimal</td>
</tr>
<tr>
<td>Typical times to peak enhancement (in brain lesions)</td>
<td>24 h $^{110}$</td>
<td>3.5–25 min $^{111}$</td>
</tr>
<tr>
<td>Signal change on T1-weighted sequence</td>
<td>Increased signal (signal decreased at very high concentrations)</td>
<td>Increased signal</td>
</tr>
<tr>
<td>Signal change on T2-weighted sequence</td>
<td>Decreased signal</td>
<td>Usually no change</td>
</tr>
<tr>
<td>Signal change on T2*-weighted sequence</td>
<td>Decreased signal</td>
<td>Decreased signal if given as a bolus</td>
</tr>
<tr>
<td>Distribution</td>
<td>Dynamic phase, blood pool phase, delayed</td>
<td>Dynamic phase, extracellular phase</td>
</tr>
<tr>
<td>Imaging dose</td>
<td></td>
<td>0.1 mmol/kg</td>
</tr>
<tr>
<td>Excretion</td>
<td>Stored with the body’s iron reserve and used in hemopoiesis coating with renal and fecal excretion</td>
<td>Renal</td>
</tr>
<tr>
<td>Boxed warning</td>
<td>Potential hypersensitivity</td>
<td>Potential NSF</td>
</tr>
</tbody>
</table>

BBB, blood-brain barrier; Gd-DTPA, gadolinium diethylenetriamine penta-acetic acid; NSF: nephrogenic systemic fibrosis.

necrosis) from intracellular iron (solid tumor). $^{39}$ T2*-weighted scans in the blood pool phase have a potential added value to standard of care by improving the visualization of abnormal vasculature. $^{40,41}$

**Differential diagnosis.** Dural-based–enhancing masses may represent benign or malignant diseases, and there is no method to effectively distinguish between these pathologies solely with GBCAs. Preliminary data suggest that delayed T1 enhancement with ferumoxytol may help distinguish between meningioma and dural metastases when used in addition to GBCA. While all dural metastases strongly enhanced with ferumoxytol and GBCAs, meningiomas showed poor to no enhancement with ferumoxytol (Figure 5). $^{42}$

Tumefactive demyelinating lesions are large lesions usually accompanied by mass effect and abnormal enhancement, mimicking brain tumors, posing a particular diagnostic dilemma in patients with or without an established diagnosis of multiple sclerosis (MS). $^{43}$ Definitive diagnosis is given after surgery and histopathologic confirmation. A noninvasive marker is highly desirable to assess this diagnostic dilemma. Ferumoxytol uptake in inflammatory lesions appears on delayed T1- and T2-weighted images $^{44}$; furthermore, perfusion MRI may help to differentiate tumors and demyelinating lesions, with relative cerebral blood volume (rCBV) being lower in tumefactive demyelinating lesions.

**Blood volume–based lesion assessment.** Measurement of the blood volume in tissues has important information regarding the level of vascularization. Small molecular weight contrast agents can only estimate blood volume using a dynamic first-pass technique. An intravascular contrast agent enables the measurement of blood volume using a steady-state technique by calculating signal differences between pre- and postcontrast (intravascular) images. This has the benefit of high spatial resolution because rapid acquisition is not required.

Dynamic susceptibility contrast perfusion-derived or steady-state cerebral blood volume (CBV) maps reflect brain tumor malignancy by revealing hypervascular, highly perfused tumor regions. rCBV (relative to a normal reference region) has been shown to correlate with survival and facilitates preoperative diagnosis by differentiating low- and high-grade tumors. $^{45}$ Moreover, elevated rCBV values can predict the transformation of low-grade gliomas into high-grade tumors 12 months before T1 enhancement appears. $^{46}$ Although these studies were performed using GBCAs, ferumoxytol-derived rCBV values were in agreement with GBCA-derived values. $^{10}$

High-grade gliomas, metastases, and to a lesser degree, primary CNS lymphomas exhibit high rCBV values with dynamic susceptibility contrast or steady-state imaging, which can help differentiate them from demyelination, abscesses, and toxoplasmosis.

**Intraoperative MRI and surgical targeting.** More aggressive, hypervascular tumor regions with high rCBV values are
Table 2 | Applications of ferumoxytol in central nervous system imaging

<table>
<thead>
<tr>
<th>MRI sequences</th>
<th>Use</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dynamic phase</td>
<td>DSC perfusion</td>
<td>DDx based on lesion vascularity</td>
<td>Low dose (1 mg/kg) needed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Preoperative grading</td>
<td>No early contrast extravasation</td>
</tr>
<tr>
<td>Blood pool phase</td>
<td>T2* - weighted(GRE)</td>
<td>Improved visualization of abnormal vessels</td>
<td>Low spatial resolution</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Improved visualization of small abnormal vessels</td>
<td>Susceptibility artifact</td>
</tr>
<tr>
<td></td>
<td>SS-CBV mapping (using pre- and post-Fe T2*w GRE scans)</td>
<td>DDx: meningioma versus metastasis</td>
<td>Motion sensitivity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Intraoperative lesion assessment</td>
<td>High spatial resolution</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Post-Sx residual tissue assessment without additional CA injection</td>
<td>Thin slices, good 3D reformats</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Differentiating intra- and extracellular iron</td>
<td>Full-brain coverage possible</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Assessment of BBB damage</td>
<td>No bolus injection needed</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lesion visualization</td>
<td>Part of most routine CNS protocols</td>
</tr>
<tr>
<td>Delayed phase</td>
<td>T1 enhancement (SE or MPRAGE)</td>
<td>Post-Sx residual tissue assessment without additional CA injection</td>
<td>Susceptibility artifact</td>
</tr>
<tr>
<td></td>
<td>High SI</td>
<td>Differentiating intra- and extracellular iron</td>
<td>Motion sensitivity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Assessment of BBB damage</td>
<td>Coregistration of the pre- and post-contrast images needed</td>
</tr>
<tr>
<td></td>
<td>T2 enhancement (T2w TSE)</td>
<td>May indicate intracerebral uptake of ferumoxytol</td>
<td>Time consuming based on coverage (5–10 min)</td>
</tr>
<tr>
<td></td>
<td>Low SI</td>
<td>Improved biopsy targeting</td>
<td>Additional scanning needed 24 h following ferumoxytol administration</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>High concentration of ferumoxytol may result in T1 signal drop</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If enhancement persists it may mimic intracerebral blood</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Additional scanning needed 24 h following ferumoxytol administration</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>If enhancement persists it may mimic intracerebral blood</td>
</tr>
</tbody>
</table>

BBB: blood-brain barrier; CA: contrast agent; CBF: cerebral blood flow; CBV: cerebral blood volume; CNS: central nervous system; CT: computed tomography; DDx: differential diagnosis; dg: diagnosis; DSC: dynamic susceptibility contrast; Fe: ferumoxytol; GBCA: gadolinium-based contrast agent; GRE: gradient echo; HGG: high-grade glioma; LGG: low-grade glioma; MPRAGE: magnetization-prepared rapid gradient-echo; MRI: magnetic resonance imaging; MTT: mean transit time; PCNSL: primary central nervous system lymphoma; rCBV: relative cerebral blood volume; SE: spin echo; SI: signal intensity; SS-CBV: steady-state cerebral blood volume; Sx: surgery; T2 TSE: T2-weighted turbo spine echo; T2*w: T2*-weighted; TTP: time to peak; 3D: 3-dimensional.

the optimal sites for biopsy and can be identified using dynamic or steady-state perfusion imaging with ferumoxytol. However, dynamic perfusion methods have limited ability to differentiate between vessels and high tissue CBV, which compromises the assessment of small active tumor hotspots that could be the source of subsequent tumor progression and short survival. Because of its near distortion-free high-resolution images, steady-state CBV mapping can overcome this limitation and may enable more precise targeting (Figure 6). Late T2 enhancement with ferumoxytol has also been described to mark specific tumor areas and may again be useful for accurate biopsy targeting. Finally, delayed enhancement with ferumoxytol enables intra- and post-operative assessment of a residual tumor without injecting additional contrast agent.

**Treatment monitoring.** After brain tumor therapy with radiation or chemoradiotherapy, an increased edema and contrast enhancement on MRI may either represent tumor progression (growing tumor mass, indicating failure of ongoing therapy) or pseudoprosperity, which is defined as a treatment-induced subacute inflammatory reaction without underlying tumor growth. Differentiating pseudoprogression from true tumor progression is a significant clinical problem. Response assessment according to the currently standard Response Assessment in Neuro-Oncology criteria is based on morphology and contrast enhancement and may delay or prevent proper therapy. Similarly, antiangiogenic drugs affect the blood-brain barrier permeability without decreasing the tumor mass itself, which can lead to a pseudoresponse that cannot be differentiated from a true response with the Response Assessment in Neuro-Oncology criteria. It is becoming apparent that a phenomenon similar to pseudoprosperity occurs after an immune checkpoint blockade for cancer therapies. This has led to the...
development of immune-related response criteria to better identify cases of pseudoprogression, although these criteria are not specific to the CNS. According to the immune-related Response Assessment in Neuro-Oncology criteria published in 2015, patients who have imaging findings that meet the Response Assessment in Neuro-Oncology criteria for progressive disease within 6 months of starting immunotherapy should undergo a confirmation of follow-up imaging (in 3 months) before defining the patients as nonresponsive to treatment. The use of CBV mapping with ferumoxytol may help determine therapeutic efficacy in a variety of CNS tumors by differentiating highly vascular malignant tumor tissue from treatment-related neuroinflammation, which correlates with survival (Figures 7 and 8).

We can now obtain high-resolution steady-state CBV images that differentiate regions of high vascularity and active tumor growth. Steady-state blood volume mapping with ferumoxytol is particularly helpful for imaging cortical lesions with an improved spatial resolution.

**Neuroinflammation and demyelination**

Delayed imaging with ferumoxytol allows the assessment of inflammation as an imaging biomarker. Few human MS investigations have been performed using ferumoxytol, but studies using other USPIOs such as ferumoxtran-10 have identified MS lesion phenotypes with the following enhancement patterns: (i) GBCA+/delayed USPIO enhancement (USPIO+), (ii) GBCA+/USPIO-, and (iii)
GBCA-/USPIO+. The USPIO-specific lesions are of particular interest because they represent endothelial activation and diapedesis without blood-brain barrier disruption. Longitudinal studies demonstrate that in a fraction of GBCA-/USPIO+ MS lesions, delayed USPIO preceded GBCA enhancement by 1 month, suggesting extensive monocyte-macrophage extravasation in MS. A study by Tagge et al. demonstrated substantially greater USPIO+ lesion volume than GBCA+ lesion volume during the acute Japanese macaque encephalomyelitis disease phase, indicating spatially and temporally extensive monocyte-macrophage migration into the CNS.

Ferumoxytol has been used to study neuroinflammatory processes associated with Japanese macaque encephalomyelitis, a demyelinating disease of the nonhuman primate with strong similarities to MS. A study by Tagge et al. demonstrated substantially greater USPIO+ lesion volume than GBCA+ lesion volume during the acute Japanese macaque encephalomyelitis disease phase, indicating spatially and temporally extensive monocyte-macrophage migration into the CNS.

Farrell et al. demonstrated delayed enhancement with ferumoxytol in patients with MS, primary CNS lymphoma, posttransplant lymphoproliferative disorder, acute...
disseminated encephalomyelitis (Figure 9), and chronic encephalitis; a higher number of lesions are visible with ferumoxytol than with GBCAs. Future applications (ultrahigh field MRI [Figure 10 shows an example how ferumoxytol improves the visualization of cerebral microvasculature at 7 T field strength], seizure imaging, functional MRI, and vascular imaging in the CNS) can be found in Supplementary Material 1.

Figure 7 | Pseudoprogression can be diagnosed using perfusion magnetic resonance imaging (MRI) with ferumoxytol and correlates with overall survival. (a) Axial MRIs of a 47-year-old woman with glioblastoma. The patient underwent T1-weighted sequences after gadolinium administration, and T2-weighted postoperative images prior to chemoradiotherapy (CRT) are shown. Eight days after CRT completion, the patient’s scans showed radiographic worsening, followed by further deterioration on follow-up MRI while the patient continued to receive adjuvant temozolomide chemotherapy. Although the updated Response Assessment in Neuro-Oncology criteria would indicate a true tumor progression, the blood volume of the lesion was low on ferumoxytol dynamic susceptibility contrast cerebral blood volume maps, which instead indicates pseudoprogression. The patient received only 3 courses of bevacizumab and continued adjuvant temozolomide. Substantial improvement is seen on the 5-month follow-up MRI after the completion of bevacizumab therapy. Seven years after the completion of CRT, the image indicates that the patient is stable without evidence of recurrence-progression (the patient is still on adjuvant temozolomide chemotherapy). (b) Kaplan-Meier estimates of overall survival with respect to the presence or absence of pseudoprogression. From Gahramanov S, Varallyay C, Tyson RM, et al. Diagnosis of pseudoprogression using MRI perfusion in patients with glioblastoma multiforme may predict improved survival. CNS Oncol. 2014;3:389–400. Reproduced with permission of Future Medicine in the format Journal/magazine via Copyright Clearance Center.

BODY IMAGING WITH FERUMOXYTOL
Liver and spleen
Metastases are the most common solid liver lesions (although benign hepatic hemangiomas are also frequent), and MRI is considered to be the definitive tool for differentiating these entities in an oncological setting. However, this task can be difficult when lesions are small or when hemangiomas are atypical or of the sclerosing subtype. In many cases,
Figure 8 | A 42-year-old male patient with glioblastoma. The T1-weighted postgadoteridol administration scan shows no-to-minimal enhancement. In contrast, a highly vascular area (arrows) is seen on high-resolution steady-state cerebral blood volume (CBV) maps obtained with ferumoxytol. Residual tumor with high CBV shows reduction following chemoradiotherapy (postsurgery scan), with a continued decrease 1 month following chemoradiotherapy, indicating a treatment response. Images provided courtesy of Edward A. Neuwelt.

Figure 9 | A patient with suspected pontine glioma was diagnosed with pontine demyelination using ferumoxytol. (a) The pre-contrast T1-weighted imaging shows little abnormality. (b) A T1-weighted sagittal magnetic resonance image (MRI) 24 hours following ultrasmall superparamagnetic iron oxide administration shows diffuse intense enhancement because of ferumoxytol uptake in the pons (arrow). (c) An axial noncontrast T2-weighted MRI shows a patchy nonspecific increased T2 signal within the pons (arrow). (d) An axial T2-weighted MRI obtained 24 hours following ferumoxytol administration shows patchy hypointensities in the pons (arrow) correlating with ferumoxytol uptake. (e) A ferumoxytol-based dynamic susceptibility contrast perfusion image shows low relative cerebral blood volume centrally within the pons (arrow) corresponding to the area of enhancing abnormality that is similar to normal-appearing white matter, a finding supportive of demyelination rather than high-grade primary central nervous system neoplasm. From Farrell BT, Hamilton BE, Dosa E, et al. Using iron oxide nanoparticles to diagnose CNS inflammatory diseases and PCNSL. Neurology. 2013;81:256–263,44 used with permission from Neurology.
small hemangiomas can be differentiated from other lesions based on the retention of intravascular contrast agents such as gadofosveset trisodium or ferumoxytol on delayed scans.57,58

Significant negative (hypointense) T2 enhancement of normal liver parenchyma is seen within 10 minutes of i.v. ferumoxytol administration. Because ferumoxytol is taken up by the MPS, it has the potential to serve as a tool for measuring MPS dysfunction. Quantitative measures of MPS function, as estimated using dynamic imaging of ferumoxytol uptake in the liver, may prove to be useful predictors of graft dysfunction and rejection, although validations in humans are still pending.59

Pancreas
Computed tomography (CT) is the imaging method of choice for pancreatic diseases, including pancreatic adenocarcinoma, pancreatitis, and neuroendocrine tumors of the pancreas. MRI of the pancreas holds significant promise secondary to the many inherent contrast mechanisms, particularly those with novel contrast agents.

Blood vessel density is known to be markedly lower in pancreatic ductal adenocarcinoma compared with that in other malignancies,60 which may explain its poor response to antiangiogenic therapies, thus making pancreatic ductal adenocarcinoma a poor choice for interrogation with dynamic techniques. Because of the long intravascular blood pool residence time, iron oxide nanoparticles offer a steady-state solution for the precise measurements of microvascular parameters, as demonstrated in preclinical studies,61–64 and are better imaging agents for pancreatic ductal adenocarcinoma. In subcutaneous xenograft models, MRI of magnetic nanoparticles provides a noninvasive, accurate assessment of fractional blood volume and vessel size index.62–72

The delayed uptake of magnetic nanoparticles by macrophages has also been a focus of MRI for multiple applications in the pancreas, including improved delineation of pancreatic adenocarcinoma17 and for quantifying inflammation in patients with early onset type 1 diabetes (Figure 11).74,75

Staging of malignant tumors
The current anatomic imaging techniques for nodal staging (e.g., CT and MRI) rely on morphologic lymph node characteristics such as size, shape, and morphology, but sensitivity for differentiating malignant lymph nodes from benign ones remains low.76 Sensitivity could be improved using USPIOs; however, most of the available data have been obtained with USPIOs other than ferumoxytol.77,78 Iron oxide particles are taken up by and retained in normal lymph nodes, resulting in signal loss on T2- and T2*-weighted images (Figure 12).79 When nodes are infiltrated with malignant cells, the nodal USPIO nanoparticle uptake capacity reduces and malignant nodes retain high signal intensity on T2*-weighted images. Optimal node T2*-weighted imaging contrast with ferumoxytol can be achieved 24 to 48 hours following injection (Figures 12 and 13).16,79

Prostate
Nodal involvement is noted in 5% to 10% of patients with prostate carcinoma, but the detection sensitivity of CT and MRI remains lower than 30%.80 Clinical experience with ferumoxytol-enhanced MRI for mapping metastatic lymph nodes in patients with prostate cancer is limited. Harisinghani et al.16 reported a significant decrease in the signal-to-noise ratio in benign nodes on T2*-weighted images but little change in the signal-to-noise ratio in malignant nodes using ferumoxytol at a dose of 4 mg/kg. MRI was performed before and 5, 18, and 24 hours after ferumoxytol injection. The most appropriate dose of ferumoxytol is uncertain because lymph nodes in the pelvis are heterogeneous. Turkbey et al.81 found that a higher dose of i.v. ferumoxytol (up to 7.5 mg/kg) was needed to completely darken the normal pelvic nodes compared with ferumoxtran-10.

Direct injection of ferumoxytol into the prostate (lymphography) has shown promise in mapping sentinel lymph nodes, as demonstrated in nonhuman primates.82 Other potential applications in body imaging (breast and sentinel lymph node, colorectal, and adrenal gland MRI and

Figure 10 | Ferumoxytol magnetic resonance angiography (MRA) improves visualization of cerebral microvasculature when compared with gadolinium MRA at 7T field strength. Gadolinium-enhanced 3-dimensional T1-weighted gradient-echo volumetric interpolated brain examination MRA of the supraclinoid internal carotid arteries (left) shows faint visualization of lenticulostriate vessels (white arrows). Ferumoxytol-enhanced MRA (right) demonstrates markedly improved visualization of the lenticulostriate microvasculature (white arrows). Images provided courtesy of Ramon Barajas.
Figure 11 | Increased pancreatic nanoparticle accumulation in patients with type 1 diabetes (T1D). Single-slice (upper row) and 3-dimensional (3D) volume sets (lower row) of a representative patient with recently diagnosed T1D (left) and a normal control subject (right). From Gaglia J, Harisinghani M, Aganj I, et al. Noninvasive mapping of pancreatic inflammation in recent-onset type-1 diabetes patients. Proc Natl Acad Sci U S A. 2015;112:2139–2144, used with permission of Proc Natl Acad Sci U S A.

Figure 12 | Benign (a,b) and malignant (c,d) nodal patterns. Axial T2*-weighted gradient-echo (GRE) pre-ferumoxytol scan (a) shows intranodal high signal (white arrows) compared with hypointensity at 24 hours post ferumoxytol scan (b), indicative of normal lymph nodes. The white arrows in (a) indicate cervical lymph nodes. Axial T2*-weighted GRE scan shows a normal, high pre-contrast intranodal signal (circle, c) compared with internal intranodal speckling (circle, d) suggesting a pathologic lymph node (black arrows indicate vascular structures). Images provided courtesy of Bronwyn E. Hamilton.
Pediatric MRI with ferumoxytol

Using ferumoxytol as an MRI agent in the pediatric population has similar potential benefits as those observed in adults. Specific advantages include separation of i.v. cannula placement/ferumoxytol administration from the MRI scanning itself (which may improve the cooperation of the child if MRI is performed without anesthesia).32 For pediatric brain tumor patients undergoing MRI with anesthesia, gadolinium and ferumoxytol in a single imaging session was well tolerated.13 Three-dimensional contrast-enhanced MR angiography (MRA) applications in pediatric CKD patients have been reported to evaluate i.v. access placement, vascular thrombosis, cardiac and renal transplantation anastomosis, re-transplantation, and biliary/liver dysfunction, thereby eliminating concerns about nephrogenic systemic fibrosis.30,31 Finally, ferumoxytol may provide a higher level of confidence for the delineation of small vessels prior to surgery in body MRA.32

Many types of lymphomas, soft tissue sarcomas, and bone sarcomas are staged with 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET)/CT.82 To provide a radiation-free alternative, whole-body diffusion-weighted MRI has been developed without the use of contrast agents. However, the use of ferumoxytol with this technique may be advantageous (Figure 15).28

**VASCULAR MRI WITH FERUMOXYTOL**

Traditional contrast-enhanced MRA employs timed, first-pass imaging of a gadolinium bolus, focused on the arterial or venous territory of interest. For the majority of GBCAs, the volume of distribution is the extracellular fluid space, which is quickly accessed after the arterial first pass. Therefore, the time window for a pure or predominantly vascular phase is very short, and the acquisition can be technically challenging. Gadofosveset is a GBCA with an extended blood residence time because of reversible binding to serum albumin. However, compared with ferumoxytol, gadofosveset has a much shorter intravascular half-life (30 minutes vs. 14 hours), and at any given time, approximately 20% of gadofosveset is distributed in the extracellular fluid space. Moreover, gadofosveset is being withdrawn from production such that by the end of 2016, ferumoxytol will be the only intravascular MRI contrast agent available for human use in the US.

Imaging in patients with a vascular disease is challenging; many (20%–30%) patients are diabetic with associated
difficult vein access\(^{93}\) and many (20%–40%) have CKD, which can prohibit the use of iodine- and gadolinium-based contrast agents.\(^{34,94}\) Ferumoxytol is a very attractive option in these patients and can be used without the need for bolus timing or complex image acquisition schemes. Ferumoxytol’s excellent safety profile has already been established in patients with chronic renal insufficiency, although it must always be used with close physiological monitoring.

In recent years, there have been several reports regarding the successful use of ferumoxytol in vascular imaging in adults and children with renal failure.\(^{30,32,34,57,91,95,96}\) The studies suggest that ferumoxytol provides similar or improved quality images compared with GBCAs, without the concerns of long-term gadolinium accumulation.\(^{1-4}\) Some of the potential applications of ferumoxytol in vascular imaging are summarized in Table 3.

**Cardiac imaging**

To date, there have been very few reports regarding the use of ferumoxytol in patients with ischemic heart disease. In patients with acute myocardial infarction, Alam \textit{et al.}\(^{97}\) and Yilmaz \textit{et al.}\(^{98}\) showed macrophage activation in injured myocardium. These authors exploited the effects of ferumoxytol in causing signal loss owing to its effect on T2 values and did not address vascular enhancement because of the shortening of T1 values.

In congenital heart disease, accurate anatomic assessment is important for surgical or interventional planning. Conventional first-pass MRA and 2-dimensional cardiac cine methods provide limited definition of intracardiac structures. In contrast, ferumoxytol supports the acquisition of 4-dimensional images of the beating heart with 4-dimensional, multiphase, steady-state imaging with contrast enhancement (Figure 16).\(^{59}\) Similarly, comprehensive motion-compensated highly accelerated 4-dimensional flow MRI with ferumoxytol enhances the quality of 4-dimensional flow information with reduced respiratory motion artifacts in children with congenital heart disease.\(^{100,101}\)

The imaging goals for most congenital heart diseases include the quantification of blood flow in the great vessels, determination of cardiac chamber volumes and contractility, and assessment of segmental anatomy. Typically, this requires a lengthy MRI scan with over an hour of repeated breath holding under anesthesia, with specialized...
technologists and physicians on hand to prescribe customized planes for image acquisition. A compelling advantage of ferumoxytol is that it enables volumetric temporally resolved high-resolution imaging without breath holding. Additionally, a free-breathing volumetric comprehensive MRI yielding flow, function, and anatomic assessment in less than 10 minutes has been achieved. Ventricular mass may be quantified with this same technique. As a result, no special operator knowledge of cardiac anatomy is required, and the duration of anesthesia and the complexity of the procedure of congenital heart MRI can be greatly reduced. These techniques stand to revolutionize the approach to MRI in children with complex congenital heart diseases.

Aortic imaging

Aortic imaging can be performed with CT angiography, noncontrast MRI, or gadolinium-enhanced MRA. Blood volume, flow measurements, and morphologic assessments can be made with contrast-enhanced MRA using a combination of time-resolved and steady-state images. Inflammation in the aortic wall can be potentially assessed using in vivo macrophage labeling with ferumoxytol, which is not available with gadolinium-enhanced imaging. Inflammation plays a key role in the progression and vulnerability of rupturing atherosclerotic plaques in many arterial territories. The presence of inflammation can also predict vessel patency.

Additionally, because of its long intravascular half-life, ferumoxytol can be used in the detection of aortic endoleaks after endovascular aneurysm repair. A systematic review showed that MRA detected almost twice as many endoleaks as CT angiography. Iron oxide-enhanced MRA (either with ferumoxytol or ferucarbotran) may be advantageous for demonstrating endoleaks.

Visceral arteries and arteriovenous fistulas

Patients with end-organ ischemia in the abdominal vasculature often have diabetes and renal insufficiency. Therefore, ferumoxytol may be a useful agent for assessing renal artery stenosis, pre- and posttransplantation vessel patency, and new venous access. In pre- and postrenal and liver transplantation patients, ferumoxytol has been used to assess vascular integrity. The frequent occurrence of venous occlusion in these patients and the requirement to confirm or re-establish venous access make high-resolution venous imaging with ferumoxytol invaluable (Figure 17).

Most studies regarding pre-fistula assessments involve pediatric patients because this group benefits the most from ferumoxytol-enhanced MRA. In a feasibility study using...
ferumoxytol for clinical pediatric cardiovascular imaging, Ruangwattanapaisarn et al. evaluated renal transplant or posttransplant complications, vascular shunts, stenosis, aneurysms, and congenital heart disease and obtained excellent image qualities of the hepatic arteries, superior mesenteric artery, renal arteries, pulmonary arteries, pulmonary veins, valves, and ventricles. Ferumoxytol-enhanced MRA consistently provided superior quality time-of-flight MRA images of patients with arteriovenous fistulas.

<table>
<thead>
<tr>
<th>Region</th>
<th>Possibilities</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>All modalities and general benefits and drawbacks</td>
<td>MRA and MRV</td>
<td>No ionizing radiation</td>
<td>Close physiological monitoring necessary</td>
</tr>
<tr>
<td></td>
<td>Vessel wall visualization</td>
<td>Nontoxic contrast agent</td>
<td></td>
</tr>
<tr>
<td></td>
<td>First-pass and steady-state images</td>
<td>Noninvasive</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Whole-body imaging</td>
<td>Multiple planes</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Long imaging window (blood pool agent)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Shows inflammation</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Highly reproducible</td>
<td></td>
</tr>
<tr>
<td>Carotid and intracerebral arteries</td>
<td>Carotid CE-MRA:</td>
<td>Direct visualization of the vessel wall</td>
<td>Close physiological monitoring necessary</td>
</tr>
<tr>
<td></td>
<td>- Vascular integrity assessment</td>
<td>Excellent soft-tissue contrast</td>
<td>Not suitable for visualizing</td>
</tr>
<tr>
<td></td>
<td>- Stenosis assessment</td>
<td>for plaque analysis</td>
<td>calcification</td>
</tr>
<tr>
<td></td>
<td>- Complete plaque morphology evaluation</td>
<td>More accurate in predicting degree</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CoW CE-MRA:</td>
<td>of stenosis than DSA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- CoW evaluation for treatment planning</td>
<td>Plaque follow-up, progression monitoring</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Silent infarction demonstration</td>
<td></td>
</tr>
<tr>
<td>Aorta</td>
<td>Aneurysm</td>
<td>Visualization of wall inflammation</td>
<td>Close physiological monitoring necessary</td>
</tr>
<tr>
<td></td>
<td>Dissection</td>
<td>More sensitive for post-EVAR endoleaks than CTA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Coarctation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Endoleak</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Infective diseases diagnosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cardiac</td>
<td>Coronary artery visualization</td>
<td>High-resolution and 3D images of the cardiac chambers and thoracic vessels</td>
<td>Close physiological monitoring necessary</td>
</tr>
<tr>
<td></td>
<td>Detection and remodeling of myocardial infarct</td>
<td>Global and regional contractile function assessment</td>
<td>Stents and metallic artifacts</td>
</tr>
<tr>
<td></td>
<td>Inflammatory diseases (myocarditis)</td>
<td>Blood flow measurements</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Congenital heart diseases</td>
<td>High sensitivity and specificity for acute inflammation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chronic heart failure measurements</td>
<td>Response monitoring for treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acute transplant rejection</td>
<td>No breath holding</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Shorter acquisition time</td>
<td></td>
</tr>
<tr>
<td>Lower extremities</td>
<td>Lower limb CE-MRA</td>
<td>Postrevascularization increased blood volume can be shown</td>
<td>Difficulty in distinguishing arteries and veins on steady-state images</td>
</tr>
<tr>
<td></td>
<td>Possibility for blood volume mapping</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Revascularization follow-up</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Visceral arteries</td>
<td>Renal artery evaluation</td>
<td>Beneficial in any stage of renal insufficiency</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kidney transplant follow-up</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mesenteric ischemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Splenic artery aneurysm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Veins</td>
<td>Vena cava and iliac vein thrombosis diagnosis and follow-up</td>
<td>The whole abdominopelvic deep venous system is assessable</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Agenesis and chronic occlusion</td>
<td>Pulmonary thromboembolism can be visualized (in major vessels)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vein mapping prior to dialysis graft placement</td>
<td>Better sensitivity for thrombus imaging than noncontrast techniques</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>No bolus needed</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Long imaging window</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Higher resolution</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fewer motion artifacts</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>High SNR</td>
<td></td>
</tr>
<tr>
<td>Pediatric</td>
<td>Congenital heart disease</td>
<td>Whole-body imaging is available</td>
<td>Sedation or anesthesia may be needed</td>
</tr>
<tr>
<td></td>
<td>Vascular malformations</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kidney diseases and transplantation follow-up</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CE-MRA, contrast-enhanced MRA; CoW, Circle of Willis; CTA, computed tomography angiography; DSA, digital subtraction angiography; EVAR, endovascular aneurysm repair; MRA, magnetic resonance angiography; MRV, magnetic resonance venography; SNR, signal-to-noise ratio; 3D, 3-dimensional.
Other applications in vascular imaging (carotid and peripheral artery imaging and MR venography) can be found in the Supplementary Material 1.

DISCUSSION
In this review, we draw attention to ferumoxytol as a contrast agent for cross-sectional imaging in patients with renal failure and highlight the various clinical indications in which ferumoxytol may not only be an alternative to GBCAs but also may be a specialized contrast agent with unique properties. These include the extended blood pool phase and uptake into the MPS in the delayed phase, where nanoparticles are metabolized as iron.

Ferumoxytol has been approved by the FDA for iron replacement in 2009, and it is available for off-label clinical use. A large and growing body of literature has been reviewed in this manuscript showing the potentials of ferumoxytol imaging. Although most available evidence is based on single-center studies, pilot studies, retrospective analyses, and preclinical results, there are new multicenter, multiphase studies being designed (clinicaltrials.gov, NCT02359097). Application for FDA approval for the use of ferumoxytol as an imaging agent is in preparation, which would further ease its widespread use in MRI.

Limitations
Besides known hypersensitivity or iron metabolic disorders, there is no absolute contraindication for ferumoxytol in MRI, and importantly, it is safe in patients with renal impairment. Vascular visualization improves early after administration, whereas late enhancement visualizes parenchymal-intracellular enhancement, which may require an additional visit, posing a logistical limitation with MRI scheduling. A signal change in the brain may persist from a few days to a week. Uptake in the liver, spleen, and bone marrow may alter MRI signal for months; therefore, radiologists must be aware of any prior history of i.v. iron oxide use. While hypersensitivity reactions occur, the incidence of serious ferumoxytol-related hypersensitivity is very low, and new FDA guidelines aim to further improve patient safety.

CONCLUSION
In conclusion, there are numerous potential applications of ferumoxytol in MRI throughout the body, including the CNS, various organs outside of the CNS, and cardiovascular system. Whether used in cases wherein GBCAs are contraindicated or for applications that are currently outside the scope of GBCAs, ferumoxytol has shown sufficient promise to warrant future investigation.
vigorou research into its ultimate clinical role. Radiological modalities that are noninvasive, radiation free, and safe are generally preferred and should be further developed; ferumoxytol MRI may be an important step in this direction.

DISCLOSURE
All the authors declared no competing interests.

ACKNOWLEDGMENTS
This work was supported in part by the National Institutes of Health grants NS053468 and CA137488-1551; in part by Federal funds from the National Cancer Institute, under Contract No. HHSN262200800001E; a Veterans Administration Merit Review Grant; and by the Walter S. and Lucienne Driskill Foundation, all to EAN. In addition, JPF was funded by R01 HL127153 IND 129441 (Feraheme as an MRI Contrast Agent for Pediatric Congenital Heart Disease - on clinical trials.gov) and HED by 2R01AR054458, R01 HD081123A, R21CA176519, R21AR066302, and R01 HL127153 IND 129441 (Feraheme as an MRI Contrast Agent for Pediatric Congenital Heart Disease - on clinical trials.gov). Lucienne Driskill Foundation, all to EAN. In addition, JPF was funded by R01 HL127153 IND 129441 (Feraheme as an MRI Contrast Agent for Pediatric Congenital Heart Disease - on clinical trials.gov) and HED by 2R01AR054458, R01 HD081123A, R21CA176519, R21AR066302, and R01 HL127153 IND 129441 (Feraheme as an MRI Contrast Agent for Pediatric Congenital Heart Disease - on clinical trials.gov).

REFERENCES

SUPPLEMENTARY MATERIAL
Supplementary Material 1. This online supplement was created as complementary material for the review to fully demonstrate the applications of ferumoxytol throughout the body. In this material we discuss the future imaging capabilities of ferumoxytol in the CNS, body, and vasculature and demonstrate all the applications in the form of an atlas with a table of contents and 54 images.

Supplementary Material 2. This table was created as supplementary material for the review in order to list the published clinical studies of ferumoxytol by clinical indication.

Supplementary material is linked to the online version of the paper at www.kidney-international.org.


